No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker Astrazeneca said on Monday that its SERENA4 Phase III trial of breast cancer treatment Etcamah (camizestrant) in combination with palbociclib did not meet its primary endpoint, although a numerical improvement in progressionfree survival was observed, as the company reaffirmed confidence in the drug's broader development programme.
Astrazeneca's study evaluated Etcamah plus palbociclib as an upfront firstline treatment for patients with ERpositive, HER2negative advanced breast cancer who had not previously received systemic therapy.
The FTSE 100-listed firm stated the outcome sharpened its focus on maximising use of Etcamah in settings where benefit has already been demonstrated, notably in patients with emergent ESR1 mutations based on the SERENA6 trial.
Astrazeneca stated the safety profile of Etcamah with palbociclib was consistent with known effects of both medicines, with no new concerns identified. Full data will be shared later. Etcamah combined with a CDK4/6 inhibitor was already approved in the US, EU, Japan and other markets for HRpositive, HER2negative advanced breast cancer upon detection of ESR1 mutation during firstline endocrine therapy.
AZN also added that Etcamah was being advanced through what it described as the most comprehensive oral SERD programme in early breast cancer, with CAMBRIA1 and CAMBRIA2 Phase III trials enrolling around 10,000 patients across intermediate and highrisk adjuvant settings
As of 1015 BST, Astrazeneca shares were up 1.67% 11,904p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS at Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.